Document is current
Any future updates will be listed below
-
Authors
Hanssen, Ruth
Rigoux, Lionel https://orcid.org/0000-0003-3761-8931
Kuzmanovic, Bojana
Iglesias, Sandra https://orcid.org/0000-0002-1778-7239
Kretschmer, Alina C. https://orcid.org/0000-0002-6323-1928
Schlamann, Marc
Albus, Kerstin https://orcid.org/0000-0003-1124-4310
Edwin Thanarajah, Sharmili
Sitnikow, Tamara
Melzer, Corina
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
Brüning, Jens C. https://orcid.org/0000-0002-6619-0092
Tittgemeyer, Marc https://orcid.org/0000-0001-5072-2149
- License Information
-
More Information
Article History
Received: 30 August 2022
Accepted: 7 July 2023
First Online: 17 August 2023
Competing interests
: O.A.C. reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer and Scynexis; consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis and Seres; honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer and Shionogi; payment for expert testimony from Cidara; participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi and The Prime Meridian Group; a patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); and other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC and Wiley. All other authors have no competing interests.
